BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of Artificial Intelligence, announced it has appointed David R. Wells to its Board of Directors, effective December 28, 2022.

Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.

UroDev Medical, a medical device company working to improve the quality of life for people who suffer from neurogenic bladder and chronic urinary retention, recently announced the appointment of Jayme Hanson to its board of directors.

Tempero Bio today announced the U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for TMP-301. TMP-301 is the Company’s investigational metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) candidate, poised for a lead indication in the treatment of cocaine use disorders (CUD).

Fabre-Kramer Pharmaceuticals, Inc. (Fabre-Kramer) today announced that on December 23, 2022, it filed an NDA Amendment with the Food and Drug Administration (FDA) for its novel mechanism antidepressant EXXUA™ (gepirone ER) for treatment of Major Depressive Disorder (MDD).

Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President, will present at the 41st Annual J.P. Morgan Healthcare Conference, being held January 9-12, 2023 in San Francisco, CA.

Biological Dynamics announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics’ proprietary technology to benefit their new company, EXOKĒRYX, Inc.

Aravive, Inc. today announced the achievement of full enrollment in the registrational Phase 3 trial of batiraxcept plus paclitaxel for platinum-resistant ovarian cancer (PROC).

Axogen, Inc. today announced that Karen Zaderej, chairman, CEO, and president, will present at the JP Morgan 41st Annual Healthcare Conference in San Francisco.